Combined Dihydroartemisinin and Eupatilin Suppress Prostate Cancer through AR-Associated Ferroptosis and Modulation of Macrophage–Tumor Crosstalk
Authors:
Open Access
- 1 January 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Abstract
Persistent androgen receptor (AR) signaling, metabolic alterations, and changes in the immune microenvironment are contributing factors to the progression of prostate cancer (PCa); however, therapeutic strategies capable of simultaneously targeting these interconnected vulnerabilities remain limited. Here, we identify a combinatorial regimen consisting of dihydroartemisinin and eupatilin (D&E) as a suppressor of PCa progression through coordinated disruption of tumor-intrinsic survival signaling and protumor immune interactions. Functionally, D&E suppressed the proliferation of PCa cells. Mechanistically, D&E induces ferroptosis in PCa cells, as evidenced by lipid peroxidation, intracellular iron accumulation, malondialdehyde elevation, and glutathione reduction. We further identified AR as an important target of D&E and found that it promotes resistance to ferroptosis by sustaining the SLC7A11 antioxidant axis through transcriptional activation of SLC7A11. Upstream, D&E inhibited the NF-κB subunit p65, which transcriptionally maintains AR expression, thus establishing an NF-κB/AR/SLC7A11 signaling cascade underlying ferroptosis resistance in PCa. Beyond tumor-intrinsic effects, D&E also remodels the tumor microenvironment. Specifically, AR-high tumor cells were found to facilitate M2-like macrophage polarization. In turn, M2-like macrophages could secrete SPP1, which potentially augments malignant properties and AR signaling in tumor cells via the CD44 pathway, thereby constituting a protumorigenic positive feedback loop. Notably, D&E attenuated the M2-like phenotype, reduced SPP1 secretion, and reduced macrophage-mediated promotion of PCa proliferation. In immunocompetent mouse models, D&E further synergized with anti-PD-L1 to suppress PCa progression. Together, these findings indicate that D&E exert antitumor effects in PCa by promoting ferroptosis-associated cell death and modulating macrophage-associated microenvironmental signaling, with potential therapeutic relevance particularly in AR-positive PCa.Keywords
Funding Information
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences and Peking Union Medical College (ZZ190504)
This publication has 63 references indexed in Scilit:
- SPP1 macrophages in colorectal cancer: Markers of malignancy and promising therapeutic targetsGenes & Diseases, 2025
- Eupatilin mitigates ICH-induced brain injury via SOX2/SLC7A11 regulation of ferroptosisNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cellsDrug Resistance Updates, 2023
- Artemisia argyi H.Lév. & Vaniot essential oil induces ferroptosis in pancreatic cancer cells via up-regulation of TFR1 and depletion of γ-glutamyl cycleFitoterapia, 2023
- Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current LimitationsCurrent Treatment Options in Oncology, 2021
- Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapyProtein & Cell, 2020
- Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancerCancer Letters, 2020
- DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritinFree Radical Biology and Medicine, 2019
- Eupatilin inhibits angiogenesis-mediated human hepatocellular metastasis by reducing MMP-2 and VEGF signalingBioorganic & Medicinal Chemistry Letters, 2018
- Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cellsCancer Letters, 2016